The role of stem cell transplantation in the management of chronic lymphocytic leukaemia

Hematol Oncol. 2009 Jun;27(2):53-60. doi: 10.1002/hon.884.

Abstract

The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic / statistics & numerical data
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Graft vs Leukemia Effect
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy / methods
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / surgery*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic / statistics & numerical data
  • Myeloablative Agonists / adverse effects
  • Myeloablative Agonists / therapeutic use
  • Salvage Therapy
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation, Autologous
  • Transplantation, Homologous
  • Treatment Outcome
  • Whole-Body Irradiation / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Myeloablative Agonists
  • Alemtuzumab